•  
  •  
 

Patrada Thanee, Center of Excellent for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Pathum Thani, Thailand and Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
Ratchaya Lertnawapan, Center of Excellent for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Pathum Thani, Thailand and Department of Internal medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
Paskorn Sritipsukho, Center of Excellent for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Pathum Thani, Thailand and Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
Sira Nanthapisal, Center of Excellent for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Pathum Thani, Thailand and Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
Prapasri Kulalert, Center of Excellent for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Pathum Thani, Thailand and Department of Pediatrics, Faculty of Medicine, Thammasat University, P
Pattara Tanticharoenwiwat, Center of Excellent for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Pathum Thani, Thailand and Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
Nitchanan Achararit, Center of Excellent for Allergy, Asthma and Pulmonary Disease, Thammasat University Hospital, Pathum Thani, Thailand and Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, T
Pongsakorn Tantilipikorn, Siriraj Clinical Research Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand and Department of Otolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Tha
Orapan Poachanukoon, Thammasat University

Keywords

Zingiber cassumunar, Phlai, Allergic rhinitis, Antihistamine, Quality of life

Abstract

Introduction: Phlai capsules can inhibit skin reactivity in allergic rhinitis patients.
Objectives: The aim of this study was to compare the efficacy of Phlai capsules with Loratadine in allergic rhinitis patients.
Methods: This was a multi-center, prospective, randomized, double-blinded, placebo-controlled study in 50 patients, aged 18-50 years old, who randomly received 4 mg or 8 mg Phlai capsules or Loratadine for 8 weeks. The primary efficacy endpoint was Total Symptoms Score at 4 and 8 weeks. The secondary endpoints were peak nasal inspiratory flow and quality of life.
Results: Demographic data was similar between groups. The change in 6-Total symptoms score decreased significantly from baseline. Peak nasal inspiratory flow increased with no significant differences between groups. According to the RCQ-36 questionnaire, there wassignificant improvement in quality of life for every domain, including sleep and emotion.
Conclusions: Phlai capsules reduced rhinitis symptoms and improved quality of life.

References

Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70(11):1372-1392.

Limvuttegrijerat T, Poachanukoon O, Koontongkaew S, Na Ayudhya TD. Crude ethanolic extracts of Zingiber cassumunar ROXB. inhibit PMA-induced MUC2 and MUC5AC expression via ERK inhibition in human airway epithelial cells. Asian Pac J Allergy Immunol. 2014;32(4):328-336.

Panthong A, Kanjanapothi D, Niwatananant W, Tuntiwachwuttikul P, Reutrakul V. Anti-inflammatory activity of compound D {(E)-4-(3',4'-dimethoxyphenyl)but-3-en-2-ol} isolated from Zingiber cassumunar Roxb. Phytomedicine. 1997;4(3):207-212.

Poachanukoon O, Meesuk L, Pattanacharoenchai N, Monthanapisut P, Dechatiwongse Na Ayudhya T, Koontongkaew S. Zingiber cassumunar ROXb. and its active constituent inhibit MMP-9 direct activation by house dust mite allergens and MMP-9 expression in PMAstimulated human airway epithelial cells. Asian Pac J Allergy Immunol. 2015;33(1):42-51.

Jitapunkul K, Poachanukoon O, Hannongbua S, Toochinda P, Lawtrakul L. Simulation Study of Interactions Between Two Bioactive Components from Zingiber cassumunar and 5-Lipoxygenase. Cell Mol Bioeng. 2017;11(1):77-89.

Tanticharoenwiwat P, Kulalert P, Dechatiwongse Na Ayudhya T, et al. Inhibitory effect of Phlai capsules on skin test responses among allergic rhinitis patients: a randomized, three-way crossover study. J Integr Med. 2017;15(6):462-468.

Khemawoot P, Hunsakunachai N, Anukunwithaya T, et al. Pharmacokinetics of Compound D, the Major Bioactive Component of Zingiber cassumunar, in Rats. Planta Med. 2016;82(13):1186-1191.

Koontongkaew S, Poachanukoon O, Sireeratawong S, et al. Safety Evaluation of Zingiber cassumunar Roxb. Rhizome Extract: Acute

and Chronic Toxicity Studies in Rats. Int Sch Res Notices. 2014;2014:632608.

Pirompanich P , Dechatiwongse Na Ayudhya T, Koontongkaew S, Poachanukoon O. A Phase I Study of Oral Phlai (Zingiber cassumunar Roxb.) Capsule in Healthy Adult Volunteers. Science & Technology Asia 2022 (in press).

Chongmelaxme B, Sruamsiri R, Dilokthornsakul P, et al. Clinical effects of Zingiber cassumunar (Plai): A systematic review. Complement Ther Med. 2017;35:70-77.

Download

Share

COinS